Rituximab shows promise for treating rare form of MG
The drug rituximab may bring long-term relief for patients with MuSK-MG, a rare form of myasthenia gravis.
News
-
-
Women with MG may experience lower quality of life than men
A recent study found that rates of anxiety, depression and fatigue are higher in women with MG than in men with the disease.
-
Study suggests COVID-19 vaccination benefits patients with myasthenia gravis
COVID-19 vaccination appears to be safe for those with myasthenia gravis and is associated with reduced infection and hospitalization rates.
-
MG drug efgartigimod may help in more ways than one
Efgartigimod may help people with MG not only by reducing harmful antibodies but also by promoting immune balance.
-
Recognizing nonmotor symptoms may improve life for people with MG
Nonmotor symptoms such as cognitive problems and sensory loss are common in myasthenia gravis and can significantly affect daily life.
-
Gender, disease severity linked to fear of MG progression
A recent study found that females and individuals with more advanced stages of disease are more likely to experience fear of MG progression.
-
Few YouTube videos on MG are actually helpful, study finds
While many YouTube videos about myasthenia gravis (MG) have moderate-to-high quality information, fewer are truly useful.
-
Gefurulimab associated with symptomatic MG improvement
Results from a clinical trial suggest that treatment with gefurulimab leads to improvement in activities of daily living in adults with MG.
-
Higher BMI may increase risk of ocular MG progression
In a recent study, patients with ocular MG were more likely to progress to generalized MG if they had a higher baseline BMI.
-
Experimental MG treatment restores muscle strength in mice
Efgartigimod restored muscle strength and helped rebalance immune cell numbers in mice with myasthenia gravis.
